CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

BACKGROUND: Epithelioid inflammatory myofibroblastic sarcoma (eIMS) is characterised by perinuclear ALK localisation, CD30 expression and early relapse despite crizotinib treatment. We aimed to identify therapies to prevent and/or treat ALK inhibitor resistance. METHODS: Malignant ascites, from an e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Fordham, Ashleigh M., Xie, Jinhan, Gifford, Andrew J., Wadham, Carol, Morgan, Lisa T., Mould, Emily V. A., Fadia, Mitali, Zhai, Lei, Massudi, Hassina, Ali, Zara S., Marshall, Glenn M., Lukeis, Robyn E., Fletcher, Jamie I., MacKenzie, Karen L., Trahair, Toby N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7524717/
https://ncbi.nlm.nih.gov/pubmed/32684628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0996-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky